Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s wins generic Zantac approval

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Dr. Reddy's Laboratories abbreviated new drug application to manufacture and market generic OTC versions of ranitidine 150 mg tablets acid indigestion treatment (GlaxoSmithKline's Zantac), Dr. Reddy's announces Sept. 13. The Hyderabad, India-based drug firm says the approval marks its first U.S. drug approval since it unveiled plans in May to launch a store-brand OTC business unit in the country. The firm is set to expand its OTC product portfolio and additional product introductions in the coming months which will include Rx switches and select OTC monograph products, the firm's North American Generics President Mark Hartman said...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel